A regulatory role for CD72 expression on B cells in systemic lupus erythematosus

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 6, 2014, Pages 767-771

  Vadasz, Zahava ^a,c   Haj, Tharwat ^a,c   Balbir, Alexandra ^b,c   Peri, Regina ^a,c   Rosner, Itzhak ^a,c   Slobodin, Gleb ^a,c   Kessel, Aharon ^a,c   Toubi, Elias ^a,c  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Autoimmunity; CD72; Regulation; SLE

Indexed keywords

AZATHIOPRINE; CD72 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; PREDNISONE; RECOMBINANT PROTEIN; SEMAPHORIN 3A; ANTINUCLEAR ANTIBODY; B LYMPHOCYTE ANTIGEN; BIOLOGICAL MARKER; CD72 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; SEMA3A PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; B CELL CULTURE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOREGULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUNG ADULT; IMMUNOLOGY; METABOLISM;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; B-LYMPHOCYTES, REGULATORY; BIOLOGICAL MARKERS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; SEMAPHORIN-3A; YOUNG ADULT;

EID: 84902546837     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.11.010     Document Type: Article

References (29)

1. Fillatreau S., Sweenie C., McGreach M., Gray D., Anderton S. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
2. Eriksson P., Sandell C., Backteman K., Ernerudh J. B cell abnormalities in Wegener's granulomatosis and microscopic polyangiitis: role of CD25+ expressing B cells. J Rheumatol 2010, 37:2086-2095.
3. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4+T cell immunity. Nat Rev Immunol 2010, 10:236-247.
4. Brisslert M., Bokarewa M., Larsson P., Wing K., Collins L.V., Tarkowski A. Phenotypic and functional characterization of human CD25+ B cells. Immunology 2006, 117:548-557.
5. Amu S., Tarkowski A., Dorner T., Bokarewa M., Brisslert M. The human immunomodulatory CD25+B cell population belongs to the memory B cell pool. Scand J Immunol 2007, 66:77-86.
6. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus. Immunity 2010, 32:129-140.
7. Kessel A., Haj T., Peri R., Snir A., Melamed D., Sabo E., et al. Human CD19+CD25 high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 2012, 11:670-677.
8. Suzuki K., Kumanogoh A., Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol 2003, 9:17-23.
9. Tordjman R., Lepelletier Y., Lemarchandel V., Cambor M., Gaulard P., Hermine O., et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002, 3:477-482.
10. Vadasz Z., Haj T., Halasz K., Rosner I., Slobodin G., Attias D., et al. Semaphorin 3A is a marker for disease activity and potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther 2012, 14:R146.
11. Catalano A. The neuroimmune semaphorin 3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 2010, 185:6373-6383.
12. Shen Y., Iqbal J., Xiao L., Lynch R., Rosenwald A., Staudt L., et al. Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. BMC Immunol 2004, 5:20-37.
13. Odendahl M., Jacobi A., Hansen A., Feist E., Hiepe F., Burmester G.R., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
14. Yamazaki T., Nagumo H., Hayashi T., Sugane K., Agematsu K. CD72-mediated suppression of human naïve B cell differentiation by down-regulating X-box binding protein 1. Eur J Immunol 2005, 35:2325-2334.
15. Anolik J.H., Barnard J., Cappionie A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
16. Adachi T., Wakabayashi C., Nakayama T., Yakura H., Tsubata T. CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol 2000, 164:1223-1229.
17. Wu H.J., Bondada S. Positive and negative roles of CD72 in B cell function. Immunol Res 2002, 25:155-166.
18. Hitomi Y., Adachi T., Tsuchiya N., Honda Z., Tokunaga K., Tsubata T. Human CD72 splicing isoform responsible for resistance to SLE regulates serum immunoglobulin level and is localized in endoplasmic reticulum. BMC Immunol 2012, 13:72.
19. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992, 35:630-640.
20. Kigel B., Varshavsky A., Kessler O., Neufeld G. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 2008, 3:e3287.
21. Dolff S., Wilde B., Patschan S., Durig J., Specker C., Philipp T., et al. Peripheral circulating activated B-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus. Scand J Immunol 2007, 66:584-590.
22. Poe J.C., Hasegawa M., Tedder T.F. CD19, CD21, and CD22: multifaceted response regulators of B lymphocvyte signal transduction. Int Rev Immunol 2001, 20:739-762.
23. Wu H.J., Bondada S. CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. J Clin Immunol 2009, 29:12-21.
24. Koenig K.F., Groeschi I., Pesickova S.S., Tesar V., Eisenberger U., Trendelenburg M. Serum cytokine profile in patients with active lupus nephritis. Cytokine 2012, 60:410-416.
25. Nakano S., Morimoto S., Suzuki J., Nozawa K., Amano H., Tokano Y., et al. Role of pathogenic autoantibody production by toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008, 47:145-149.
26. Kessel A., Rosner I., Halasz K., Grushko G., Shoenfeld Y., Paran D., et al. Antibody clustering helps refine lupus prognosis. Semin Arthritis Rheum 2008, 39:66-70.
27. Dyson J.K., McPherson S., Anstee Q.M. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013, 66:1033-1045. [Epub ahead of print]. 10.1136/jclinpath-2013-201620.
28. Abignano G., Cuomo G., Buch M.H., Rosenberg W.M., Valentini G., Emery P., et al. The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overallfibrosis in systemic sclerosis. Ann Rheum Dis 2013, 72:1845-1852. [Epub ahead of print].
29. Cordiali-Fei P., Mussi A., D'Agosto G., Trento E., Bordignon V., Trincone S., et al. Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol 2013, 2013:390563. [Epub 2013 May 29]. 10.1155/2013/390563.